Connect Biopharma Holdings Ltd
Datakwaliteit: 100%
CNTB
Nasdaq
Manufacturing
Chemicals
€ 2,80
▲
€ 0,17
(6,46%)
Marktkapitalisatie: 158,26 M
Prijs
€ 2,80
Marktkapitalisatie
158,26 M
Dagbereik
€ 2,58 — € 2,87
52-Weeksbereik
€ 0,60 — € 3,82
Volume
245.127
Openen € 2,61
50D / 200D Gem.
€ 2,71
3,44% above
50D / 200D Gem.
€ 2,13
31,68% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -51,64 M
Capital intensive — 678,13% of revenue goes to capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-99,75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-87,57%
Onder sectorgemiddelde (-53,41%)
ROIC-71,73%
Net Margin-86687,50%
Op. Margin-90740,63%
Veiligheid
Debt / Equity
N/A
Current Ratio5,48
Interest CoverageN/A
Waardering
PE (TTM)
-2,85
Onder sectorgemiddelde (-1,48)
P/B Ratio2,86
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,9 | -1,5 |
| P/B | 2,9 | 1,6 |
| ROE % | -87,6 | -53,4 |
| Net Margin % | -86687,5 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -99,75% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 64.000,0 | Net Income (TTM) | -55,48 M |
| ROE | -87,57% | ROA | -73,93% |
| Gross Margin | N/A | Operating Margin | -90740,63% |
| Net Margin | -86687,50% | Free Cash Flow (TTM) | -51,64 M |
| ROIC | -71,73% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5,48 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | 51,17 M | Tangible Book Value | 55,32 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,85 | Forward P/E | N/A |
| P/B Ratio | 2,86 | P/S Ratio | 2472,81 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -32,63% | ||
| Market Cap | 158,26 M | Enterprise Value | 120,41 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,00 | Revenue / Share | 0,00 |
| FCF / Share | -0,91 | OCF / Share | -0,91 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 678,13% | FCF Conversion | 93,08% |
| SBC-Adj. FCF | -55,37 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 64.000,0 | 26,03 M |
| Net Income | -55,48 M | -15,63 M |
| EPS (Diluted) | -1,00 | -0,28 |
| Gross Profit | — | — |
| Operating Income | -58,07 M | -22,45 M |
| EBITDA | — | — |
| R&D Expenses | 37,80 M | 29,26 M |
| SG&A Expenses | — | — |
| D&A | 704.000,0 | 660.000,0 |
| Interest Expense | — | — |
| Income Tax | 197.000,0 | 223.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 56,08 M | 101,28 M |
| Total Liabilities | 14,10 M | 9,12 M |
| Shareholders' Equity | 41,98 M | 92,17 M |
| Total Debt | — | — |
| Cash & Equivalents | 38,35 M | 78,23 M |
| Current Assets | 50,93 M | 96,96 M |
| Current Liabilities | 13,61 M | 8,46 M |
{"event":"ticker_viewed","properties":{"ticker":"CNTB","listing_kind":"stock","pathname":"/stocks/cntb","exchange":"Nasdaq","country":"US"}}